drugset / Trial / NCT06890598
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
RandomizedParallel-groupDouble-blindTreatment
Summary
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.
Timeline
- Start
- 2025-03-27
- Primary completion
- 2029-05
- Completion
- 2032-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olomorasib | Small molecule | — | Oral |
| Background | Durvalumab | Monoclonal antibody | — | Intravenous |
| Background | Pembrolizumab | Monoclonal antibody | — | Intravenous |